{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T09:25:34Z","timestamp":1793179534850,"version":"4.5.0"},"reference-count":146,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014653","name":"NIHR Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015652","name":"Barts Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015652","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011703","name":"Yorkshire Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ajog.2026.02.020","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T07:11:48Z","timestamp":1771225908000},"page":"260-279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk of ovarian cancer in women with a pathogenic or likely pathogenic variant in NBN: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"235","author":[{"given":"Subhasheenee","family":"Ganesan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Dibden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Sideris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonetta","family":"Malan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Oxley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Sia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamda","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Flaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Brentnall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin T.","family":"Fierheller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Gareth","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3381-5057","authenticated-orcid":false,"given":"Ranjit","family":"Manchanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2026.02.020_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ajog.2026.02.020_bib2","series-title":"Cancer Tomorrow. A tool that predicts the future cancer incidence and mortality burden worldwide from the current estimates in 2022 up until 2045","author":"Ferlay","year":"2022"},{"key":"10.1016\/j.ajog.2026.02.020_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/srep29506","article-title":"Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients","volume":"6","author":"George","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajog.2026.02.020_bib4","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib5","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.3390\/cancers13174344","article-title":"Implementation of multigene germline and parallel somatic genetic testing in epithelial ovarian cancer: SIGNPOST study","volume":"13","author":"Chandrasekaran","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ajog.2026.02.020_bib6","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41436-018-0406-9","article-title":"BOADICEA: a comprehensive breast cancer risk prediction modelincorporating genetic and nongenetic risk factors","volume":"21","author":"Lee","year":"2019","journal-title":"Gene Med"},{"key":"10.1016\/j.ajog.2026.02.020_bib7","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/jmedgenet-2021-107904","article-title":"Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors","volume":"59","author":"Lee","year":"2022","journal-title":"J Med Genet"},{"key":"10.1016\/j.ajog.2026.02.020_bib8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00439-016-1663-9","article-title":"Assessing the genetic architecture of epithelial ovarian cancer histological subtypes","volume":"135","author":"Cuellar-Partida","year":"2016","journal-title":"Hum Genet"},{"key":"10.1016\/j.ajog.2026.02.020_bib9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"JNCI J Nat Cancer Inst"},{"key":"10.1016\/j.ajog.2026.02.020_bib11","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/ijc.33378","article-title":"Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels","volume":"148","author":"Crosbie","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajog.2026.02.020_bib12","article-title":"Ovarian cancer: identifying and managing familial and genetic risk-summary of new NICE guidance","volume":"385","author":"Slade","year":"2024","journal-title":"Bmj"},{"key":"10.1016\/j.ajog.2026.02.020_bib13","first-page":"e16","article-title":"Risk-Reducing salpingo-oophorectomy and the use of hormone replacement therapy below the age of natural menopause: scientific impact paper no. 66 October 2021: scientific impact paper no. 66","volume":"129","author":"Manchanda","year":"2022","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2026.02.020_bib14","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/jmedgenet-2016-103800","article-title":"Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis","volume":"53","author":"Manchanda","year":"2016","journal-title":"J Med Genet"},{"key":"10.1016\/j.ajog.2026.02.020_bib15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2015.10.001","article-title":"Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women","volume":"139","author":"Manchanda","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib16","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ajog.2026.02.020_bib17","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1136\/jmg.40.12.e131","article-title":"Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility","volume":"40","author":"Heikkinen","year":"2003","journal-title":"J Med Gene"},{"key":"10.1016\/j.ajog.2026.02.020_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2174\/138920208784533610","article-title":"NBS1 heterozygosity and cancer risk","volume":"9","author":"di Masi","year":"2008","journal-title":"Curr Genomics"},{"key":"10.1016\/j.ajog.2026.02.020_bib19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0092-8674(00)81175-7","article-title":"The hMre11\/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response","volume":"93","author":"Carney","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ajog.2026.02.020_bib20","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.dnarep.2004.03.004","article-title":"Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks","volume":"3","author":"Digweed","year":"2004","journal-title":"DNA Repair"},{"key":"10.1016\/j.ajog.2026.02.020_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv214","article-title":"Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer","volume":"107","author":"Ramus","year":"2015","journal-title":"JNCI J Nat Cancer Inst"},{"key":"10.1016\/j.ajog.2026.02.020_bib22","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/ijc.35066","article-title":"Germline pathogenic variants in the MRE11, RAD50, and NBN (MRN) genes in cancer predisposition: a systematic review and meta-analysis","volume":"155","author":"Stastna","year":"2024","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajog.2026.02.020_bib23","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41431-025-01786-0","article-title":"Exome sequencing identifies HELB as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancer","volume":"33","author":"Dicks","year":"2025","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ajog.2026.02.020_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2017.08.030","article-title":"Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls","volume":"147","author":"Lilyquist","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib25","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3390\/cancers12040956","article-title":"Multigene panel germline testing of 1333 Czech patients with ovarian cancer","volume":"12","author":"Lhotova","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajog.2026.02.020_bib26","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1200\/JCO.18.01854","article-title":"Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients","volume":"37","author":"Kurian","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib27","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2026.02.020_bib28","unstructured":"Wells G.A.S.B., O\u2019Connell D., Peterson J., Welch V., Losos M., Tugwell P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. The Ottawa Hospital Research Institute, 20. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp#:\u223c:text=It%20was%20developed%20to%20assess%20the%20quality%20of,quality%20assessments%20in%20the%20interpretation%20of%20meta-analytic%20results. Accessed February 5, 2025."},{"key":"10.1016\/j.ajog.2026.02.020_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010403","article-title":"Empirical evaluation of the Q-Genie tool: a protocol for assessment of effectiveness","volume":"6","author":"Sohani","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.ajog.2026.02.020_bib30","doi-asserted-by":"crossref","first-page":"11.10.1","DOI":"10.1002\/0471250953.bi1110s43","article-title":"From FastQ data to high confidence variant calls: the genome analysis toolkit best practices pipeline","volume":"43","author":"Van der Auwera","year":"2013","journal-title":"Curr Protoc Bioinformatics"},{"key":"10.1016\/j.ajog.2026.02.020_bib31","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ajog.2026.02.020_bib32","volume":"2025","year":"2023"},{"key":"10.1016\/j.ajog.2026.02.020_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1111191","article-title":"Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases","volume":"13","author":"Alenezi","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib34","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4274\/MMJ.galenos.2022.22556","article-title":"Multigene panel testing in Turkish hereditary cancer syndrome patients","volume":"37","author":"Arslan Ates","year":"2022","journal-title":"Medeni Med J"},{"key":"10.1016\/j.ajog.2026.02.020_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100235","article-title":"Impact of deleterious variants in other genes beyond BRCA1\/2 detected in breast\/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge","volume":"6","author":"Bono","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ajog.2026.02.020_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/gtmb.2021.0108","article-title":"New perspectives on the recurrent monoallelic germline mutations of DNA repair and checkpoint genes and clinical variability","volume":"26","author":"Sahin","year":"2022","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1016\/j.ajog.2026.02.020_bib37","article-title":"Mutational landscape for Indian hereditary breast and ovarian cancer cohort suggests need for identifying population specific genes and biomarkers for screening","volume":"10","author":"Kadri","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib38","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1007\/s11033-020-05378-7","article-title":"Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic","volume":"47","author":"Riedlova","year":"2020","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.ajog.2026.02.020_bib39","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1002\/ijc.31992","article-title":"The identification of pathogenic variants in BRCA1\/2 negative, high risk, hereditary breast and\/or ovarian cancer patients: high frequency of FANCM pathogenic variants","volume":"144","author":"Schubert","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajog.2026.02.020_bib40","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00439-017-1845-0","article-title":"Expanding the spectrum of germline variants in cancer","volume":"136","author":"Siraj","year":"2017","journal-title":"Hum Genet"},{"key":"10.1016\/j.ajog.2026.02.020_bib41","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3343\/alm.2020.40.2.148","article-title":"Clinical validity of next-generation sequencing multi-gene panel testing for detecting pathogenic variants in patients with hereditary breast-ovarian cancer syndrome","volume":"40","author":"Yoo","year":"2020","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.ajog.2026.02.020_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178450","article-title":"Reanalysis of BRCA1\/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability","volume":"12","author":"Stafford","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ajog.2026.02.020_bib43","article-title":"Targeted sequencing for hereditary breast and ovarian cancer in BRCA1\/2-negative families reveals complex genetic architecture and phenocopies","volume":"5","author":"Plowman","year":"2024","journal-title":"HGG Adv"},{"key":"10.1016\/j.ajog.2026.02.020_bib44","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13048-023-01119-z","article-title":"Targeted next-generation sequencing of 21 candidate genes in hereditary ovarian cancer patients from the Republic of Bashkortostan","volume":"16","author":"Prokofyeva","year":"2023","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.ajog.2026.02.020_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-66324-2","article-title":"A comprehensive analysis of germline predisposition to early-onset ovarian cancer","volume":"14","author":"Horackova","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajog.2026.02.020_bib46","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s00432-018-2763-9","article-title":"Multigene panel testing beyond BRCA1\/2 in breast\/ovarian cancer Spanish families and clinical actionability of findings","volume":"144","author":"Bonache","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib47","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s10689-025-00471-x","article-title":"Detection rates of multigene panel and exome testing in patients with previous negative BRCA1\/2 results","volume":"24","author":"Wasson","year":"2025","journal-title":"Fam Cancer"},{"key":"10.1016\/j.ajog.2026.02.020_bib48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2015.12.017","article-title":"Genetic characterization of early onset ovarian carcinoma","volume":"140","author":"Bernards","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib49","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2018.09.030","article-title":"Germline pathogenic variants identified in women with ovarian tumors","volume":"151","author":"Carter","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib50","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/gim.2015.166","article-title":"Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing","volume":"18","author":"Susswein","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.ajog.2026.02.020_bib51","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","article-title":"Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG oncology\/gynecologic oncology group study","volume":"24","author":"Norquist","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajog.2026.02.020_bib52","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajog.2026.02.020_bib53","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/gim.2015.212","article-title":"Improving performance of multigene panels for genomic analysis of cancer predisposition","volume":"18","author":"Shirts","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.ajog.2026.02.020_bib54","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1038\/ncomms4156","article-title":"Integrated analysis of germline and somatic variants in ovarian cancer","volume":"5","author":"Kanchi","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajog.2026.02.020_bib55","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-021-06152-4","article-title":"Thai patients who fulfilled NCCN criteria for breast\/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing","volume":"188","author":"Lertwilaiwittaya","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajog.2026.02.020_bib56","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.20.03661","article-title":"Therapeutic implications of germline testing in patients with advanced cancers","volume":"39","author":"Stadler","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib57","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ygyno.2023.04.024","article-title":"Germline drivers of gynecologic carcinosarcomas","volume":"174","author":"Sia","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib58","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/mgg3.157","article-title":"Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer","volume":"3","author":"Hirotsu","year":"2015","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.ajog.2026.02.020_bib59","article-title":"Exome sequencing identifies HELB as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancer","author":"Dicks","year":"2024","journal-title":"medRxiv"},{"key":"10.1016\/j.ajog.2026.02.020_bib60","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1111\/cas.16367","article-title":"Prevalence and outcomes of germline pathogenic variants of homologous recombination repair genes in ovarian cancer","volume":"115","author":"Miwa","year":"2024","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ajog.2026.02.020_bib61","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/jog.16026","article-title":"Multi-gene panel analysis in BRCA1\/2-negative patients suspected of hereditary breast and ovarian cancer syndrome: real-World data from a single institution","volume":"50","author":"Nakahara","year":"2024","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.ajog.2026.02.020_bib62","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ygyno.2015.01.537","article-title":"Hereditary predisposition to ovarian cancer, looking beyond BRCA1\/BRCA2","volume":"137","author":"Minion","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib63","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.20.02785","article-title":"Time trends in receipt of germline genetic testing and results for women diagnosed with breast cancer or ovarian cancer, 2012-2019","volume":"39","author":"Kurian","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib64","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamaoncol.2015.2690","article-title":"Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment","volume":"1","author":"Desmond","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib65","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13073-022-01101-2","article-title":"Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients","volume":"14","author":"Ceyhan-Birsoy","year":"2022","journal-title":"Genome Med"},{"key":"10.1016\/j.ajog.2026.02.020_bib66","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jmoldx.2020.01.013","article-title":"Germline mutation in 1338 BRCA-negative Chinese hereditary breast and\/or ovarian cancer patients: clinical testing with a multigene test panel","volume":"22","author":"Kwong","year":"2020","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ajog.2026.02.020_bib67","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10086","article-title":"Patterns and functional implications of rare germline variants across 12 cancer types","volume":"6","author":"Lu","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajog.2026.02.020_bib68","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41467-020-15461-z","article-title":"Exome sequencing of familial high-grade serous ovarian carcinoma reveals heterogeneity for rare candidate susceptibility genes","volume":"11","author":"Subramanian","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajog.2026.02.020_bib69","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41436-019-0633-8","article-title":"A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients","volume":"22","author":"LaDuca","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.ajog.2026.02.020_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186043","article-title":"Prevalence of deleterious germline variants in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1)","volume":"12","author":"Harter","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ajog.2026.02.020_bib71","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ygyno.2023.11.019","article-title":"Pathogenic germline variants in non-BRCA1\/2 homologous recombination genes in ovarian cancer: analysis of tumor phenotype and survival","volume":"180","author":"Kahn","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib72","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/cancers10110442","article-title":"Spectrum and prevalence of pathogenic variants in ovarian cancer susceptibility genes in a group of 333 patients","volume":"10","author":"Koczkowska","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajog.2026.02.020_bib73","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s10038-019-0562-z","article-title":"Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia","volume":"64","author":"Krivokuca","year":"2019","journal-title":"J Hum Genet"},{"key":"10.1016\/j.ajog.2026.02.020_bib74","doi-asserted-by":"crossref","first-page":"314","DOI":"10.12788\/jcso.0181","article-title":"Hereditary cancer testing in patients with ovarian cancer using a 25-gene panel","volume":"14","author":"Langer","year":"2016","journal-title":"J Comm Supp Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib75","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.26437","article-title":"Prevalence and landscape of pathogenic or likely pathogenic germline variants and their association with somatic phenotype in unselected Chinese patients with gynecologic cancers","volume":"6","author":"Wen","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ajog.2026.02.020_bib76","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/ijc.32304","article-title":"Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels","volume":"145","author":"Feliubadal\u00f3","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajog.2026.02.020_bib77","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10549-017-4181-0","article-title":"Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients","volume":"163","author":"Crawford","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajog.2026.02.020_bib78","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13053-019-0119-3","article-title":"Age-adjusted association of homologous recombination genes with ovarian cancer using clinical exomes as controls","volume":"17","author":"Arvai","year":"2019","journal-title":"Hered Cancer Clin Pract"},{"key":"10.1016\/j.ajog.2026.02.020_bib79","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1158\/1055-9965.EPI-23-0041","article-title":"Germline mutations in 12 genes and risk of ovarian cancer in three population-based cohorts","volume":"32","author":"Kotsopoulos","year":"2023","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ajog.2026.02.020_bib80","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.3390\/cancers13153659","article-title":"TUMOSPEC: a Nation-wide study of hereditary breast and ovarian cancer families with a predicted pathogenic variant identified through multigene panel testing","volume":"13","author":"Lesueur","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajog.2026.02.020_bib81","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13048-023-01234-x","article-title":"Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer","volume":"16","author":"Adamson","year":"2023","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.ajog.2026.02.020_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1030786","article-title":"Germline and somatic variants in ovarian carcinoma: a Next-Generation Sequencing (NGS) analysis","volume":"12","author":"Andrikopoulou","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib83","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10549-020-05633-2","article-title":"Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants","volume":"181","author":"Bernstein-Molho","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajog.2026.02.020_bib84","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41525-019-0087-6","article-title":"High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer","volume":"4","author":"Bertelsen","year":"2019","journal-title":"NPJ Genom Med"},{"key":"10.1016\/j.ajog.2026.02.020_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.698595","article-title":"Analysis of sequence and copy number variants in Canadian patient cohort with familial cancer syndromes using a unique next generation sequencing based approach","volume":"12","author":"Bhai","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.ajog.2026.02.020_bib86","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/jog.13287","article-title":"High-risk epithelial ovarian cancer patients for hereditary ovarian cancer","volume":"43","author":"Chirasophon","year":"2017","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.ajog.2026.02.020_bib87","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41431-022-01098-7","article-title":"The genetics of hereditary cancer risk syndromes in Brazil: a comprehensive analysis of 1682 patients","volume":"30","author":"de Oliveira","year":"2022","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ajog.2026.02.020_bib88","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.0307","article-title":"Gene sequencing for pathogenic variants among adults with breast and ovarian cancer in the Caribbean","volume":"4","author":"George","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ajog.2026.02.020_bib89","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3390\/genes13081398","article-title":"Examining the diagnostic yield of tumour testing and qualifying germline concordance for hereditary cancer variants in patients with high-grade serous carcinoma","volume":"13","author":"Goebel","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ajog.2026.02.020_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415789","article-title":"Clinical impact of next-generation sequencing multi-gene panel highlighting the landscape of germline alterations in ovarian cancer patients","volume":"23","author":"Gurioli","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajog.2026.02.020_bib91","doi-asserted-by":"crossref","first-page":"112258","DOI":"10.18632\/oncotarget.22733","article-title":"Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer","volume":"8","author":"Hirasawa","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ajog.2026.02.020_bib92","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55515-x","article-title":"Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients","volume":"9","author":"Jarhelle","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajog.2026.02.020_bib93","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41525-024-00400-4","article-title":"Germline mutations of 4567 patients with hereditary breast-ovarian cancer spectrum in Thailand","volume":"9","author":"Kansuttiviwat","year":"2024","journal-title":"NPJ Genom Med"},{"key":"10.1016\/j.ajog.2026.02.020_bib94","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.1940","article-title":"Germline mutations in Chinese ovarian cancer with or without breast cancer","volume":"10","author":"Kwong","year":"2022","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.ajog.2026.02.020_bib95","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00432-020-03377-6","article-title":"Multigene panel testing for hereditary breast and ovarian cancer in the province of Ontario","volume":"147","author":"Lerner-Ellis","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib96","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13048-019-0560-y","article-title":"Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study","volume":"12","author":"Li","year":"2019","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.ajog.2026.02.020_bib97","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/jhg.2016.4","article-title":"Detection of high frequency of mutations in a breast and\/or ovarian cancer cohort: implications of embracing a multi-gene panel in molecular diagnosis in India","volume":"61","author":"Mannan","year":"2016","journal-title":"J Hum Genet"},{"key":"10.1016\/j.ajog.2026.02.020_bib98","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3389\/fonc.2019.01429","article-title":"Latin American study of hereditary breast and ovarian cancer LACAM: a genomic epidemiology approach","volume":"9","author":"Oliver","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib99","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1055\/s-0042-1746197","article-title":"Comprehensive germline genomic profiling of patients with ovarian cancer: a cross-sectional study","volume":"43","author":"Pramanik","year":"2022","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib100","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/cas.14242","article-title":"Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals","volume":"111","author":"Shao","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ajog.2026.02.020_bib101","article-title":"Next-generation sequencing-based analysis of homologous recombination repair gene variant in ovarian cancer","volume":"10","author":"Song","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ajog.2026.02.020_bib102","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.3390\/cancers14061434","article-title":"Real-World data on detection of germline and somatic pathogenic\/likely pathogenic variants in BRCA1\/2 and other susceptibility genes in ovarian cancer patients using next generation sequencing","volume":"14","author":"Stegel","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajog.2026.02.020_bib103","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/1878-0261.13430","article-title":"Comprehensive profiling of pathogenic germline large genomic rearrangements in a pan-cancer analysis","volume":"17","author":"Sun","year":"2023","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib104","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12967-020-02391-z","article-title":"A comprehensive custom panel evaluation for routine hereditary cancer testing: improving the yield of germline mutation detection","volume":"18","author":"Vel\u00e1zquez","year":"2020","journal-title":"J Transl Med"},{"key":"10.1016\/j.ajog.2026.02.020_bib105","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.3390\/cancers15092534","article-title":"Incidence and prognostic impact of deleterious germline mutations in primary advanced ovarian carcinoma patients","volume":"15","author":"Imterat","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajog.2026.02.020_bib106","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ygyno.2019.12.010","article-title":"Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making","volume":"156","author":"Jorge","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib107","doi-asserted-by":"crossref","first-page":"358","DOI":"10.5306\/wjco.v10.i11.358","article-title":"Germline mutations in Thai patients with nonmucinous epithelial ovarian cancer","volume":"10","author":"Manchana","year":"2019","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib108","first-page":"1","article-title":"Genetic and clinical analysis of epithelial ovarian cancer in Greek patients","volume":"4","author":"Plevris","year":"2020","journal-title":"Cancer Rep Rev"},{"key":"10.1016\/j.ajog.2026.02.020_bib109","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jogc.2022.06.005","article-title":"Low BRCA1 and BRCA2 germline mutation rates in a French-Canadian population with a diagnosis of epithelial tubo-ovarian carcinoma","volume":"44","author":"Bernard","year":"2022","journal-title":"J Obstet Gynaecol Canada"},{"key":"10.1016\/j.ajog.2026.02.020_bib110","doi-asserted-by":"crossref","first-page":"47064","DOI":"10.18632\/oncotarget.16791","article-title":"Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer","volume":"8","author":"Tedaldi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ajog.2026.02.020_bib111","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5579543","article-title":"Identifying sequence variants of 18 hereditary ovarian cancer-associated genes in Chinese epithelial ovarian cancer patients","volume":"2021","author":"Wu","year":"2021","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ajog.2026.02.020_bib112","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1038\/s41598-024-52707-y","article-title":"Characteristics of germline DNA damage response gene mutations in ovarian cancer in Southwest China","volume":"14","author":"Fu","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajog.2026.02.020_bib113","article-title":"Germline mutational landscape and novel targetable RAD51D variant in Chinese patients with ovarian cancer","volume":"10","author":"Feng","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib114","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jmoldx.2015.04.009","article-title":"A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients","volume":"17","author":"Lincoln","year":"2015","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ajog.2026.02.020_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105758","article-title":"Impact of germline variants on breast and ovarian cancer risk in Japanese women: an original cohort study and meta-analysis","volume":"116","author":"Yazaki","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ajog.2026.02.020_bib116","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ygyno.2025.08.016","article-title":"Germline landscape of high grade serous ovarian cancer across age groups: is age just a number?","volume":"201","author":"Sia","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib117","doi-asserted-by":"crossref","DOI":"10.1111\/cge.70138","article-title":"Prevalence of germline variants in breast, ovarian, and prostate cancer in Uruguay","author":"Alzogaray","year":"2026","journal-title":"Clin Genet"},{"key":"10.1016\/j.ajog.2026.02.020_bib118","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1186\/s12885-025-14989-x","article-title":"Germline and somatic mutational variants of Tunisian high grade serous ovarian cancer identified by next-generation sequencing","volume":"25","author":"Ammous-Boukhris","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ajog.2026.02.020_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2024.1611813","article-title":"Molecular genetic investigation of hereditary breast and ovarian cancer patients in the Southern Transdanubian region: widening the mutation spectrum and searching for new pathogenic variants using next-generation methods","volume":"30","author":"Bar\u00e1ti","year":"2024","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.ajog.2026.02.020_bib120","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.3390\/cancers16142563","article-title":"Genetic testing uptake among ovarian cancer survivors in the genetic risk analysis in ovarian cancer (GRACE) study","volume":"16","author":"White","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajog.2026.02.020_bib121","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.32195","article-title":"Estimands for clinical effectiveness of risk-reducing early salpingectomy in women with high risk of ovarian cancer","volume":"8","author":"Sia","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ajog.2026.02.020_bib122","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/humu.22981","article-title":"HGVS recommendations for the description of sequence variants: 2016 update","volume":"37","author":"den Dunnen","year":"2016","journal-title":"Hum Mutat"},{"key":"10.1016\/j.ajog.2026.02.020_bib123","doi-asserted-by":"crossref","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","article-title":"ClinVar: public archive of relationships among sequence variation and human phenotype","volume":"42","author":"Landrum","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ajog.2026.02.020_bib124","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.ejhg.5200554","article-title":"Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populations","volume":"8","author":"Varon","year":"2000","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ajog.2026.02.020_bib125","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1750-1172-7-13","article-title":"Nijmegen breakage syndrome (NBS)","volume":"7","author":"Chrzanowska","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ajog.2026.02.020_bib126","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41572-019-0113-0","article-title":"Chromosome instability syndromes","volume":"5","author":"Taylor","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ajog.2026.02.020_bib127","volume":"2025","year":"2024"},{"key":"10.1016\/j.ajog.2026.02.020_bib128","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejogrb.2024.06.025","article-title":"British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: recommendations for practice update 2024","volume":"300","author":"Moss","year":"2024","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2026.02.020_bib129","article-title":"Ovarian cancer: identifying and managing familial and genetic risk-summary of new NICE guidance","volume":"385","author":"Slade","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2026.02.020_bib130","doi-asserted-by":"crossref","first-page":"264","DOI":"10.5694\/mja2.52227","article-title":"Screening and prevention of ovarian cancer","volume":"220","author":"Sideris","year":"2024","journal-title":"Med J Aust"},{"key":"10.1016\/j.ajog.2026.02.020_bib131","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1200\/OP.21.00382","article-title":"Risk-reducing bilateral salpingo-oophorectomy for ovarian cancer: a review and clinical guide for hereditary predisposition genes","volume":"18","author":"Liu","year":"2022","journal-title":"JCO Oncol Prac"},{"key":"10.1016\/j.ajog.2026.02.020_bib132","volume":"2026","year":"2025"},{"key":"10.1016\/j.ajog.2026.02.020_bib133","volume":"2026","year":"2026"},{"key":"10.1016\/j.ajog.2026.02.020_bib134","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","article-title":"Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer","volume":"195","author":"Piek","year":"2001","journal-title":"J Pathol"},{"key":"10.1016\/j.ajog.2026.02.020_bib135","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajog.2026.02.020_bib136","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","article-title":"Intraepithelial carcinoma of the Fimbria and pelvic serous carcinoma: evidence for a causal relationship","volume":"31","author":"Kindelberger","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajog.2026.02.020_bib137","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/path.6322","article-title":"The genomic trajectory of ovarian high-grade serous carcinoma can be observed in STIC lesions","volume":"264","author":"Cheng","year":"2024","journal-title":"J Pathol"},{"key":"10.1016\/j.ajog.2026.02.020_bib138","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.5219","article-title":"Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions","volume":"248","author":"Wu","year":"2019","journal-title":"J Pathol"},{"key":"10.1016\/j.ajog.2026.02.020_bib139","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/ijgc-2020-001541","article-title":"Preventing Ovarian Cancer Through Early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial","volume":"31","author":"Gaba","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ajog.2026.02.020_bib140","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/ijgc-2023-004377","article-title":"TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol","volume":"33","author":"Steenbeek","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ajog.2026.02.020_bib141","doi-asserted-by":"crossref","first-page":"TPS10615","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS10615","article-title":"NRG-CC008: a nonrandomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers [SOROCk]","volume":"40","author":"Huh","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib142","first-page":"869","article-title":"Tubal origin of ovarian endometriosis and clear cell and endometrioid carcinoma","volume":"5","author":"Wang","year":"2015","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ajog.2026.02.020_bib143","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ygyno.2014.10.009","article-title":"Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States","volume":"136","author":"Fuh","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib144","article-title":"Global incidence of ovarian cancer according to histologic subtype: a population-based cancer registry study","volume":"10","author":"Wang","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.ajog.2026.02.020_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102983","article-title":"Worldwide patterns and trends in ovarian cancer incidence by histological subtype: a population-based analysis from 1988 to 2017","volume":"79","author":"Wei","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ajog.2026.02.020_bib146","doi-asserted-by":"crossref","first-page":"W420","DOI":"10.1093\/nar\/gkac373","article-title":"IBS 2.0: an upgraded illustrator for the visualization of biological sequences","volume":"50","author":"Xie","year":"2022","journal-title":"Nucleic Acids Res"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937826000840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937826000840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:35:46Z","timestamp":1790123746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937826000840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":146,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0002937826000840"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2026.02.020","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of ovarian cancer in women with a pathogenic or likely pathogenic variant in NBN: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2026.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}